DeepMed Research

Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

Phase 2

Recruiting

Conditions: Ulcerative Colitis

Interventions: Drug: BI 3032950 intravenous (Part A)
Drug: BI 3032950 subcutaneous (Part B)

First Posted Date: 2024-10-15

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT06636656

Locations: 🇵🇱
Clinical Research Center, Poznan, Poland
🇺🇸
Peak Gastroenterology Associates, Colorado Springs, Colorado, United States
🇺🇸
Medical Research Center of Connecticut, LLC, New Haven, Connecticut, United States

and more 47 locations

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Phase 3

Recruiting

Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis

Interventions: Drug: Survodutide
Drug: Placebo

First Posted Date: 2024-10-09

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1800

Registration Number: NCT06632444

Locations: 🇺🇸
Arizona Liver Health-Chandler-68733, Chandler, Arizona, United States
🇺🇸
The Institute for Liver Health, LLC, Tucson, Arizona, United States
🇺🇸
Scottsdale Clinical Trials, Scottsdale, Arizona, United States

and more 444 locations

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Phase 3

Recruiting

Conditions: Metabolic Dysfunction Associated Steatohepatitis

Interventions: Drug: Survodutide
Drug: Placebo matching survodutide

First Posted Date: 2024-10-09

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1590

Registration Number: NCT06632457

Locations: 🇨🇳
Changzhou Third People's Hospital, Changzhou Shi, China
🇨🇳
West China Hospital of Sichuan University, Chengdu, China
🇺🇸
The Institute for Liver Health, LLC, Tucson, Arizona, United States

and more 419 locations

A Study to Test How Well Different Doses of BI 3810477 Are Tolerated by Healthy Men

Phase 1

Active, not recruiting

Conditions: Healthy

Interventions: Drug: BI 3810477
Drug: Placebo

First Posted Date: 2024-10-08

Last Posted Date: 2025-05-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT06631430

Locations: 🇧🇪
SGS Life Science Services - Clinical Research, Edegem, Belgium

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1291583

First Posted Date: 2024-10-08

Last Posted Date: 2025-05-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT06631417

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether BI 1356225 Improves Impulsive Behavior in Men With Opioid Use Disorder Who Are Taking Buprenorphine

Phase 1

Recruiting

Conditions: Opioid Use Disorder

Interventions: Drug: BI 1356225
Drug: Placebo

First Posted Date: 2024-10-08

Last Posted Date: 2025-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06628622

Locations: 🇺🇸
Collaborative Neuroscience Research, LLC, Los Alamitos, Los Alamitos, California, United States
🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸
iResearch Atlanta, Decatur, Georgia, United States

and more 2 locations

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Phase 3

Recruiting

Conditions: Pyoderma Gangrenosum

Interventions: Drug: Placebo matching to spesolimab
Drug: Spesolimab
Drug: Prednisone
Drug: Prednisolone

First Posted Date: 2024-10-03

Last Posted Date: 2025-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 90

Registration Number: NCT06624670

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States
🇺🇸
University of California Irvine, Orange, California, United States

and more 84 locations

A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Nerandomilast, Formulation 1
Drug: Nerandomilast, Formulation 2

First Posted Date: 2024-10-02

Last Posted Date: 2025-02-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT06624072

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine

Phase 2

Recruiting

Conditions: Solid Tumours

Interventions: Drug: Brigimadlin

First Posted Date: 2024-10-01

Last Posted Date: 2025-05-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT06619509

Locations: 🇭🇺
Clinexpert Gyongyos, Gyongyos, Hungary
🇯🇵
Okayama University Hospital, Okayama, Okayama, Japan
🇩🇪
Universitätsklinikum Frankfurt, Frankfurt, Germany

and more 53 locations

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

Phase 2

Recruiting

Conditions: Solid Tumours

Interventions: Drug: Zongertinib

First Posted Date: 2024-09-03

Last Posted Date: 2025-04-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT06581432

Locations: 🇫🇷
CTR Georges-François Leclerc, Dijon, France
🇧🇪
Edegem - UNIV UZ Antwerpen, Edegem, Belgium
🇺🇸
Alaska Oncology and Hematology, LLC, Anchorage, Alaska, United States

and more 61 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy